Loading stock data…
Artivion, Inc. (AORT)
$25.45-0.13 (-0.49%)
Market OpenUpdated 3:20 PM EDT
Artivion, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artivion, Inc. in the Healthcare sector is trading at $25.45 with a market capitalization of $1.2B. Wall Street consensus targets $42.15 (8 analysts), implying a +65.7% move over the next 12 months. The stock is currently 47% below its 52-week high of $48.25, remaining 24.3% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +65.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 22) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $116.34M↑ | $115.99M↑ | $113.39M↑ | $112.97M↑ | $98.98M |
| Gross Profit | $75.45M↑ | $73.14M↓ | $74.39M↑ | $73.11M↑ | $63.58M |
| Operating Income | $5.79M↓ | $7.18M↓ | $9.04M↑ | $8.38M↑ | $2.15M |
| Net Income | $1.42M↓ | $2.43M↓ | $6.50M↑ | $1.34M↑ | -$505,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.71%
Volume
Today's trading volume
314,507
Recent News
3 Russell 2000 Stocks Walking a Fine Line
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Artivion (AORT) Stock Looks Cheap On Cash Flow But Pricey On Sales
Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount. With the Discounted Cash Flow (DCF) estimate and market multiples both pointing to pricing that looks broadly in line with fundamentals, the stock no longer looks obviously cheap or obviously expensive. Artivion is up 57.6% over three years. This means anyone looking at the stock today is...
Artivion (AORT) Bounces As AMDS Launch Narrative Keeps Fair Value In Focus
Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026. Artivion’s recent 1 day share price return of 3.11% comes after a 7 day share price decline of 5.62%, with the stock still showing a year to date share price loss of 38.82%. The 3 year total shareholder return is 55.25%, suggesting longer term holders have seen a very different experience to recent buyers. Balance...
1 High-Flying Stock to Own for Decades and 2 Facing Challenges
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
Why Artivion (AORT) Stock Is Trading Up Today
Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on the stock to $40 from $39 while maintaining a Buy rating.